United Therapeutics EVP & General Counsel Executes 10b5-1 Option Exercise and Sale

Executive Summary

On September 18, 2026, United Therapeutics Corp ($UTHR) reported insider transactions executed by Paul A. Mahon, Executive Vice President and General Counsel. On September 17, 2026, Mahon exercised stock options for 8,300 shares at a strike price of $146.03 and subsequently sold all 8,300 underlying shares across multiple market tranches at a volume-weighted average price of approximately $497.54 per share. Total gross proceeds from the sale were approximately $4,129,608.

Transaction Details

• Derivative Exercise: 8,300 stock options exercised at $146.03 per share ($1,212,049 cost basis), expiring March 15, 2027.
• Sales: 8,300 shares sold in seven tranches ranging from $495.09 to $501.61 per share.
• Net Proceeds (pre-tax): Approximately $2,917,559 above exercise cost.
• Post-Transaction Holdings: Mahon retains direct ownership of 45,172 shares of common stock and 47,540 derivative stock options.

Context and Trading Significance

The trading significance is assessed as Low. The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on August 11, 2025. Standard option exercise and immediate disposition under an established 10b5-1 plan reflects planned executive compensation realization rather than a discretionary market-timing decision.